These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17582148)

  • 1. Characterization of immune reactivity profiles using microarray technology may expedite identification of candidate antigens for next generation malaria vaccines.
    Parekh FK; Richie TL
    Clin Chem; 2007 Jul; 53(7):1183-5. PubMed ID: 17582148
    [No Abstract]   [Full Text] [Related]  

  • 2. Profiling the antibody immune response against blood stage malaria vaccine candidates.
    Gray JC; Corran PH; Mangia E; Gaunt MW; Li Q; Tetteh KK; Polley SD; Conway DJ; Holder AA; Bacarese-Hamilton T; Riley EM; Crisanti A
    Clin Chem; 2007 Jul; 53(7):1244-53. PubMed ID: 17510307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines against the blood stages of falciparum malaria.
    Miller LH; Good MF; Kaslow DC
    Adv Exp Med Biol; 1998; 452():193-205. PubMed ID: 9889974
    [No Abstract]   [Full Text] [Related]  

  • 4. Pfs230: from malaria transmission-blocking vaccine candidate toward function.
    Williamson KC
    Parasite Immunol; 2003 Jul; 25(7):351-9. PubMed ID: 14521577
    [No Abstract]   [Full Text] [Related]  

  • 5. The case for a subunit vaccine against malaria.
    Anders RF
    Trends Parasitol; 2011 Aug; 27(8):330-4. PubMed ID: 21592861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malaria vaccines based on the Plasmodium falciparum merozoite surface protein 3--should we avoid amino acid sequence polymorphisms or embrace them?
    Saul A
    J Infect Dis; 2007 Jan; 195(2):171-3. PubMed ID: 17191161
    [No Abstract]   [Full Text] [Related]  

  • 7. [The immunological aspects of tropical malaria related to the development of an antimalarial vaccine].
    Chirkov VP; Popov AF
    Med Parazitol (Mosk); 2000; (2):56-8. PubMed ID: 10900926
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview: immunology of malaria and progress in malaria vaccine development.
    Tharavanij S
    Southeast Asian J Trop Med Public Health; 1992 Sep; 23 Suppl 4():71-87. PubMed ID: 1364871
    [No Abstract]   [Full Text] [Related]  

  • 9. An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum.
    Lalvani A; Aidoo M; Allsopp CE; Plebanski M; Whittle HC; Hill AV
    Res Immunol; 1994; 145(6):461-8. PubMed ID: 7534937
    [No Abstract]   [Full Text] [Related]  

  • 10. The hope but challenge for developing a vaccine that might control malaria.
    Good MF
    Eur J Immunol; 2009 Apr; 39(4):939-43. PubMed ID: 19350585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The naturally acquired immunity in severe malaria and its implication for a PfEMP-1 based vaccine.
    Chen Q
    Microbes Infect; 2007 May; 9(6):777-83. PubMed ID: 17398133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda.
    Kanoi BN; Takashima E; Morita M; White MT; Palacpac NM; Ntege EH; Balikagala B; Yeka A; Egwang TG; Horii T; Tsuboi T
    Vaccine; 2017 Feb; 35(6):873-881. PubMed ID: 28089547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
    Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
    Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malaria vaccine based on self-assembling protein nanoparticles.
    Burkhard P; Lanar DE
    Expert Rev Vaccines; 2015; 14(12):1525-7. PubMed ID: 26468608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria.
    Ballou WR; Kester KE; Heppner DG
    Chem Immunol; 2002; 80():253-61. PubMed ID: 12058643
    [No Abstract]   [Full Text] [Related]  

  • 16. A malaria vaccine adjuvant based on recombinant antigen binding to liposomes.
    Huang WC; Deng B; Lin C; Carter KA; Geng J; Razi A; He X; Chitgupi U; Federizon J; Sun B; Long CA; Ortega J; Dutta S; King CR; Miura K; Lee SM; Lovell JF
    Nat Nanotechnol; 2018 Dec; 13(12):1174-1181. PubMed ID: 30297818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
    Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
    Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine efficacy: winning a battle (not war) against malaria.
    Van de Perre P; Dedet JP
    Lancet; 2004 Oct 16-22; 364(9443):1380-3. PubMed ID: 15488199
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malaria vaccine development: lessons from the field.
    Todryk S; Bejon P
    Eur J Immunol; 2009 Aug; 39(8):2007-10. PubMed ID: 19672893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.